Table 5.
Demographics of the sevoflurane and propofol groups in patients who underwent unilateral THA
| Variables | Propofol (n = 91) | Sevoflurane (n = 91) | p value |
|---|---|---|---|
| Age (years) | 60.18 ± 13.30 | 60.02 ± 13.13 | 0.959 |
| Male, n (%) | 28 (30.77) | 30 (32.97) | 0.663 |
| BMI (kg/M2) | 26.59 ± 4.44 | 25.45 ± 4.28 | 0.074 |
| Chronic diseases | |||
| Hypertension | 30 (32.97) | 38 (41.76) | 0.273 |
| Diabetes | 9 (9.89) | 10 (10.98) | 0.710 |
| Coronary artery disease | 2 (2.20) | 2 (2.20) | 1.000 |
| Arrhythmia | 1 (1.10) | 1 (1.10) | 1.000 |
| CNS disease | 1 (1.10) | 4 (4.39) | 0.391 |
| Asthma/COPD | 0 (0) | 0 (0) | NA |
| Malignancy | 1 (1.10) | 2 (2.20) | 0.687 |
| Duration of surgery (min) | 42.88 ± 7.39 | 43.73 ± 9.91 | 0.543 |
| Duration of anesthesia (min) | 70.73 ± 8.40 | 73.51 ± 10.79 | 0.078 |
| Duration of PACU stay (min) | 79.26 ± 19.82 | 76.82 ± 16.24 | 0.056 |
| Intraoperative blood loss (mL) | 254.48 ± 120.36 | 254.20 ± 133.26 | 0.620 |
| Hospitalization (day) | 3.01 ± 0.10 | 3.03 ± 0.16 | 0.460 |
| Bupivacaine dose | 274.21 ± 29.56 | 275.450 ± 23.32 | 0.732 |
| Pain score at 24 h (NRS) | 2.18 ± 0.76 | 2.08 ± 0.31 | 0.769 |
Central nervous system (CNS) disease includes history of stroke, Parkinson’s disease, and brain tumor. Data are presented as number (%) or mean ± standard deviation. Continuous variables were compared using independent sample T-test, while categorical variables were analyzed using Fisher’s exact tests. *p < 0.05 represented a significant difference between two groups. Abbreviation: BMI, body mass index; COPD, chronic obstructive pulmonary disease; CNS, central nervous system; NRS, numeric rating scale; THA, total hip arthroplasty; PACU, post-anesthesia care unit